All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
UK Vol.169 (pharmaceutical corporations: AstraZeneca)
追加(本日までのツイート)
White blood cells produce antibodies in response to infection. Over 25 years, @croweje and @VUMC_Vaccines have pioneered techniques for isolating human “monoclonal” antibodies to neutralize pathogenic viruses with a laser-like focus. #COVID19 @AstraZeneca https://t.co/yomHmoGDpW
— VUMC Insights (@VUMC_Insights) October 14, 2020
Read Heather Macdonald-Tait’s account of what motivated her to volunteer for a trial of the #COVID19 vaccine developed by @UniofOxford and @AstraZeneca, and her experiences so far: https://t.co/LYpCFkxVbE
— Gavi, the Vaccine Alliance (@gavi) October 14, 2020
US Signs Deal With @AstraZeneca to Develop, Make #COVID19 Antibody Treatment
Learn more: https://t.co/oJncXqIEB1 pic.twitter.com/Bb8LWIbq5o
— AJMC (@AJMC_Journal) October 10, 2020
We’re partnering w/ @JPEOCBRND & @AstraZeneca under #WarpSpeed on clinical trials and large-scale manufacturing of a monoclonal antibody therapeutic to prevent #COVID19. With @US_FDA authorization, the doses could be used to help fight the pandemic https://t.co/ugxfm9LQyw pic.twitter.com/TUHAQMtLNU
— BARDA (@BARDA) October 9, 2020
.@BARDA, @JPEOCBRND & @AstraZeneca are working together at #WarpSpeed on clinical trials and large-scale manufacturing of a medicine to prevent #COVID19. The government will own these first doses and can make them available with authorization from @US_FDA. https://t.co/7LP5tF4rCf pic.twitter.com/924YcaCEvW
— ASPR (@PHEgov) October 9, 2020
Due to a month-long halt of the trial imposed by #US regulators investigating potential side-effects, volunteers have only been given one dose of the vaccine #COVID19 #Oxford @AstraZeneca https://t.co/NYt8lWVaHM
— Arab News (@arabnews) October 7, 2020
US Govt has awarded $486 million to @AstraZeneca PLC to develop & secure supplies of up to 1 lk doses of #COVID19 antibody treatment, a similar class of drug that was used in treating President #Trump: US Health Dept@realDonaldTrump @AstraZenecaUS pic.twitter.com/ahDVDSne3n
— ET NOW (@ETNOWlive) October 12, 2020
The U.S. government and @AstraZeneca have teamed up to develop 100,000 doses of #COVID19 antibody treatments for high-risk populations, with the possibility for the U.S. to acquire an additional 1,000,000 doses in 2021.
Learn more, via @CNBC https://t.co/A22Y0hOkLp
— Solomon McCown & Cence (@solomonmccown) October 12, 2020
A #COVID19 #vaccine trial by @UniofOxford and @AstraZeneca was paused last month due to a reported side effect in a patient.
But how common is pausing a vaccine trial? How does the trial resume? Do vaccine companies really treat safety seriously?@Dr_Banika explains: pic.twitter.com/3nkwwA9pLy— hospital research (@hosp_research) October 13, 2020
.@AstraZeneca received $1.2 BILLION to develop a #COVID19 vaccine from the US government. But that didn't satisfy their greed.
Since their Texas-sized payday, the company announced price hikes on many of their products TWICE. https://t.co/GdaTXQnzJk
— Texans For Affordable Rx (@TX4AffordableRx) October 8, 2020
After @Novartis & @AstraZeneca J&J puts on hold it’s #COVID19 trial due to unexplained illness in participant… All this isn’t surprising. Beyond the hype, reality of #clinicaltrials catches up with us… It’s a long, risky & unpredictable endeavor. https://t.co/YWV56CNFqA
— Amine Korchi MD (@AmineKorchiMD) October 13, 2020
#US, @AstraZeneca sign pact for #COVID19 antibody treatment used to treat #Trump https://t.co/ulVrswN2gD | #pharma #pharmanews #IndiaIncfightsCovid19
— ExpPharma (@ExpPharma) October 11, 2020
Let's talk about some real COVID19 drugs for a moment. The one drug that really helped me in my own COVID19 infection was Symbiocort by @AstraZeneca. I already had some at home for my asthma: my doc in Canada had given me a free sample he'd gotten from his drug rep. 1/ https://t.co/AKb6IAi6Y2
— Shawn Wenzel (@shawnwenzel) October 8, 2020
“Front-runners @Pfizer and @AstraZeneca say they have no plans to do challenge studies. Other #vaccine makers like @JNJNews are eyeing them cautiously… @moderna_tx has started manufacturing a strain of the virus that could be used for challenge studies…” #COVID19 #compliance https://t.co/McIgobW16i
— Mark Warner (@MAAWLAW) October 13, 2020
US backs @AstraZeneca #COVID19 antibody drug with $486M in funding. Read more at: https://t.co/tsxzEXmJIv
—#biomanufacturing #biopharma #pharmaceutical #pharma #vaccine pic.twitter.com/feSd63P3Qm
— American Biomanufacturing (@BioMfg) October 13, 2020
Pharma continue to hold the reins. "MoU between @AstraZeneca and a Brazilian manufacturer, which has been seen by @financialtimes, defines the “Pandemic Period” as ending on July 1 2021." #COVID19
https://t.co/2iBoiiC4Gz— Shailly Gupta (@Shaillytweeting) October 7, 2020
Mergers & Acquisitions explores 5 ways the #coronavirus is changing #dealmaking, as pharmaceutical companies such as @sanofi and @astrazeneca scramble to develop vaccines, diagnostic tools and treatments https://t.co/wvz94Eh9iZ
— Mergers&Acquisitions (@TheMiddleMarket) October 7, 2020
EMA begins real-time review of @AstraZeneca's #COVID19 vaccine: https://t.co/lHiEaN1tfE @EMA_News #clinicaltrials #COVID #CoronaVirus #Vaccine
— Teckro (@teckroofficial) October 9, 2020
Cambridge trio accelerate COVID-19 initiatives https://t.co/cLkjZ8M5oH @AstraZeneca @GileadSciences @sanofi @UniofOxford #COVID19 #coronavirus #Remdesivir pic.twitter.com/pfmZB60RxB
— Business Weekly (@businessweekly) October 8, 2020
Great news. The two vaccines for COVID-19: One is being developed by the company @AstraZeneca, Cambridge, UK, in collaboration with the University of Oxford, the other by @BioNTech_Group, Mainz, Germany, in collaboration with @pfizer, NY, USA. #COVID19. By @ChemistryViews https://t.co/sNXkzsF82d
— Química y Sociedad (@ForoQyS) October 8, 2020
Staffordshire is set to receive 600,000 doses of coronavirus vaccination from as early as November! It's great to hear that a vaccine to combat #COVID19 is being manufactured @KeeleUniversity following an agreement between @CobraBiologics & @AstraZeneca UK https://t.co/eXw21WRYO5
— Croft Architecture (@CroftArchitects) October 8, 2020
AstraZeneca eligible for provisional registration of Covid-19 vaccine after ruling by Therapeutic Goods Administration. News via @CanberraIQ for your daily news digest. For a free trial: https://t.co/jLzrWSAOYG @TGAgovau @AstraZeneca #COVID19 #pandemic https://t.co/hGDtvFgyl5
— Canberra IQ (@CanberraIQ) October 11, 2020
A vaccine to treat COVID-19 globally is imminent but its likely effectiveness has been laid bare. @AstraZeneca @pfizer @JennerInstitute #COVIDVaccine #Vaccinehttps://t.co/iir1So9X2O
— The CEO Magazine (@TheCEOMagazineG) October 14, 2020
ツイッター検索で 上記製薬会社 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
We are thrilled to be building on our long-standing heritage in breast cancer through our collaboration announced today with Daiichi Sankyo. To learn more about why we believe pioneering new treatments in this area are so important, click here: https://t.co/1Haz3gHlud pic.twitter.com/pkXJnovNgz
— AstraZeneca (@AstraZeneca) March 29, 2019
AstraZeneca-Daiichi Sankyo's gastric cancer drug wins approval in Japan @AstraZeneca #daiichisankyo https://t.co/n2VmONPEKA pic.twitter.com/oaN0SVZtB1
— Market Intelligence: Healthcare (@SPGMIHealthcare) September 28, 2020
AstraZeneca to pay Daiichi Sankyo $1B up front in #cancer drug collaboration @AstraZeneca @DaiichiSankyo #dealmakinghttps://t.co/HjFewEzOS1 pic.twitter.com/8gdC72bRiM
— Market Intelligence: Healthcare (@SPGMIHealthcare) July 27, 2020
AstraZeneca-Daiichi Sankyo drug gets US FDA breakthrough tag for lung #cancer @AstraZeneca #enhertu https://t.co/8JOmhiH3dh pic.twitter.com/Gg2Bcxhuat
— Market Intelligence: Healthcare (@SPGMIHealthcare) May 18, 2020
COVID-19 Vaccine: AstraZeneca AZD1222 phase 1/2 trials to begin in Japan @AstraZeneca,@DaiichiSankyo #astrazeneca #astrazenecanews #clinicaltrial #coronavirus #covid-19 #coronavirusvaccine #azd1222 #daiichisankyo #jcrpharma https://t.co/ndeokzCfcI
— Medical Dialogues (@medicaldialogs) September 6, 2020
AstraZeneca, Daiichi Sankyo gets USFDA Breakthrough Therapy status for lung cancer drug Enhertu @AstraZeneca,@DaiichiSankyo #astrazeneca #cancer #enhertu https://t.co/6pyPdJqecP
— Medical Dialogues (@medicaldialogs) May 19, 2020
.@AstraZeneca has agreed a global development and #commercialization deal with @DaiichiSankyoUS, worth up to $6 billion for the Japanese #pharma. The deal centers on Daiichi Sankyo’s TROP2-directed antibody drug conjugate DS-1062 https://t.co/VC2DGKjyWP pic.twitter.com/BA6qSTSzWf
— CHEManager International (@CHEManager_EU) August 6, 2020
.@AstraZeneca has agreed to develop .@DaiichiSankyoUK Phase I cancer antibody drug conjugate DS-1062 worldwide except Japanhttps://t.co/jeq0LARzDm
DS-1062 is a trophoblast cell-surface antigen 2 -directed ADC for non-small cell lung cancer and triple negative breast cancer.— Decipher Analytics (@DecipherAnalyt2) July 30, 2020
@AstraZeneca bets up to $6 billion on new Daiichi cancer drug.https://t.co/CvDOIuBdVj
— TheNewsPanels (@TheNewsPanels) July 29, 2020
A look at some of the success factors behind yesterday's mammoth ADC deal with @AstraZeneca #pharma #biotech
Oncology Deal-Making The Daiichi Way https://t.co/NPnpZgejGG
— Ian Haydock (@ScripIanHaydock) July 28, 2020
AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | @AstraZeneca @ImmunomedicInc @Pfizer @DaiichiSankyo #pancsm #lungcancer #cancer #breastcancer #Biotech #NewJersey https://t.co/QV27IJeUjW
— Aspen Biosciences (@aspenbio) July 27, 2020
AstraZeneca & Daiichi Sankyo enter collaboration to develop and commercialise new ADC https://t.co/c3BBGtcTba @AstraZeneca @EUdaiichisankyo More European life science business news at [LSE] at https://t.co/df6Gi5dTPT pic.twitter.com/E3kdckFgzF
— [iito] Life Science (@iitoLifeScience) July 27, 2020
.@AstraZeneca pays $1B upfront & ~$5B milestones to codevelop DS-1062 w/ @DaiichiSankyo outside of Japan
TROP2-directed DXd #antibody-drug conjugate is currently in Ph1 #clinicaltrials vs #NSCLC & #TNBChttps://t.co/pXa46t3W6S#immunooncology #ADC #LungCancer #BreastCancer pic.twitter.com/jjm8bKCcyb
— DDNews Online (@DDNewsOnline) July 27, 2020
@AstraZeneca strengthens Daiichi Sankyo partnership with new development of a novel antibody drug conjugate (ADC) for the treatment of a number of multiple tumours which express the cell-surface glycoprotein TROP2https://t.co/aUefWC4btv vía @pmlivecom
— Jose Antonio Gasquet (@jagasquet) July 27, 2020
.@AstraZeneca & Daiichi have also been in talks over the supply of the British company's potential coronavirus vaccine in Japan.https://t.co/k1kqx6uYuL
— CNBC-TV18 (@CNBCTV18Live) July 27, 2020
.@AstraZeneca could pay up to $6 billion to #Japan's Daiichi Sankyo to develop and market a type of targeted cancer treatment in the second multi-billion dollar #cancer drug collaboration between the two companies.https://t.co/5CoLjHOdY9
— The Jerusalem Post (@Jerusalem_Post) July 27, 2020
AstraZeneca Collaborates with Daiichi Sankyo to Evaluate the Combination of Patritumab Deruxtecan (U3-1402) + Tagrisso for EGFR-Mutated Non-Small Cell Lung Cancer @AstraZeneca @DaiichiSankyoUS https://t.co/GegHhaEVis pic.twitter.com/y5XRj56gWY
— PharmaShots – Incisive news in 3 shots (@Pharmashot) August 7, 2020
Daiichi Sankyo in Talks with AstraZeneca for the Supply of AZD1222 to Combat COVID-19 in Japan @AstraZeneca @DaiichiSankyohttps://t.co/xcsgbutsPz pic.twitter.com/T6p9mCQ6YE
— PharmaShots – Incisive news in 3 shots (@Pharmashot) June 29, 2020
AstraZeneca and Daiichi Sankyo Provide Updates of Enhertu (fam-trastuzumab deruxtecan-nxki) in HER2-Positive Metastatic Colorectal Cancer and HER2-Mutant Non-Small Cell Lung Cancer #ASCO20 @AstraZeneca @ASCO https://t.co/ukMWYKFZfo pic.twitter.com/SjMNX4tMH6
— PharmaShots – Incisive news in 3 shots (@Pharmashot) June 1, 2020
AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi Sankyo for $6.9B @AstraZeneca
https://t.co/zV274HcNZW— PharmaShots – Incisive news in 3 shots (@Pharmashot) April 1, 2019
One of @AstraZeneca's most decisive moves last year came when it signed a multi-billion dollar deal with @EUdaiichisankyo, focused on just one breast cancer drug. We spoke with Daiichi's @GillesJAGallant about the future plans for the drug https://t.co/C4VAEammCR pic.twitter.com/6NeXkiU5Kf
— pharmaphorum (@pharmaphorum) January 30, 2020
Results from a piviotal study of @AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan, showed that women with breast cancer who had not responded to around six prior treatment courses saw no further progression for a median of 16.4 months https://t.co/TL1sLOmgf6
— pharmaphorum (@pharmaphorum) December 12, 2019
AstraZeneca, Daiichi Sankyo get Orphan Drug Designation for gastric cancer drug Enhertu @AstraZeneca #astrazeneca #enhertu #usfda #daiichisankyo #gastriccancer #trastuzumabderuxtecan https://t.co/ofKbiL4T8M
— Medical Dialogues (@medicaldialogs) May 25, 2020
Rare disease: Enhertu of @AstraZeneca and Daiichi Sankyo now with Orphan Drug Designation in the US for treatment of gastric cancer https://t.co/IZqqD1DNTf #gastricCancer #rarediseases #cancers #oncology pic.twitter.com/npY2FpPoZF
— EuropaWire (@europawire) May 22, 2020
From the Center for Biosimilars, @AstraZeneca + Daiichi-Sankyo win @US_FDA OK for #trastuzumab antibody conjugate #Enhertu https://t.co/s2E3s6bSr8
— AJMC-Oncology (@EBOncology) December 23, 2019
FDA accepts BLA from AstraZeneca and Daiichi for targeted chemotherapy@AstraZeneca @DaiichiSankyo #oncologydrugs #targetedchemotherapy https://t.co/NB0YHsLwUI
— Pharma Tech Focus (@PharmaTechFocus) October 18, 2019
AstraZeneca and Daiichi Sankyo sign $6.9bn cancer drug development deal @AstraZeneca @EUdaiichisankyo #cancerdrugdevelopment #bigpharmadealtshttps://t.co/lWXBRDSHS8
— Pharma Tech Focus (@PharmaTechFocus) March 29, 2019
Full house at AstraZeneca Exchange event at the Judge Business School, University of Cambridge. Fascinating insight to the recent AZ/Daiichi Sankyo deal from the people who made it happen @AstraZeneca @CambridgeJBS pic.twitter.com/CaN7n8PAw2
— Milner Institute (@TheMilnerInst) July 3, 2019
@AstraZeneca and Daiichi's #HER2 ADC hits goal in pivotal trial https://t.co/E0rhjfKnGX
— Miles Collier (@MilesCollier) May 8, 2019
.@AstraZeneca has signed a $6.9bn collaboration with Daiichi Sankyo to co-partner on cancer drug DS8201. Read full note here @LiberumToday #aim #shareshttps://t.co/R2styv9Pxs pic.twitter.com/trsEc3uZiW
— Research Tree (@research_tree) April 5, 2019
@AstraZeneca signs $6.9B deal with Daiichi Sankyo for #cancertherapy #healthcare #news https://t.co/kw2IhwuIBT
— Healthcare Opportunities (@HealthcareOppo1) April 3, 2019
.@AstraZeneca will pay up to $6.9 billion in #cancer drug deal with Daiichi and more for #pharma #marketers to know. #drugprices #DTC $JNJ $AZN $GILD https://t.co/CIJqaYE6LJ pic.twitter.com/j6VKJgbvgW
— MM+M Magazine (@MMMnews) April 1, 2019
.@AstraZeneca and Daiichi Sankyo brought us a huge deal last night. We worked on the Top 20 #cancer deals with @JohnCendpts at @endpts with data from @DealForma $AZNhttps://t.co/HJjEAS19Gz
— Chris Dokomajilar (@ChrisDoko) March 29, 2019
.@AstraZeneca sought to buy Japan's Daiichi Sankyo last year https://t.co/BQ6IFBwu8l pic.twitter.com/s933R4Glvb
— The Business Times (@BusinessTimes) August 31, 2017
#AZN £85.95 #AI #PHARMA$AZN & Daiichi Sankyo enter collaboration to develop & commercialise new #antibody drug✅
Calquence recommended for approval in the EU for chronic #leukaemia✅
Imfinzi recommended for approval in the EU for small cell lung #cancer✅https://t.co/pRRm18hjeI pic.twitter.com/uHD3PLkvay— Peter Higgins (conkers) (@conkers3) July 27, 2020
#AZN-4% £62.05 $3.5Bn #Placing & collaboration w/ Daiichi Sankyo for #HER2 ADC #trastuzumab deruxtecan (DS-8201) w/ upfront payment of $1.35B, plus up to $5.55B include $3.8B for regulatory & other milestones, as well as $1.75B for sales-related milestones https://t.co/Lj8lTxIsdL pic.twitter.com/YmjCiZF2TR
— Peter Higgins (conkers) (@conkers3) March 29, 2019
AstraZeneca Resumes Clinical Study of its COVID-19 Vaccine in Japan @AstraZeneca https://t.co/l8IrrMu0oz pic.twitter.com/Wyn0BkNSKz
— PharmaShots – Incisive news in 3 shots (@Pharmashot) October 5, 2020
AstraZeneca and MSD’s Selumetinib Receive MHLW’s Orphan Drug Designation for Neurofibromatosis Type 1 in Japan @AstraZeneca @Merck https://t.co/azsnR93iP5 pic.twitter.com/34oe5UGj9p
— PharmaShots – Incisive news in 3 shots (@Pharmashot) June 30, 2020
.@AstraZeneca Plc said on Friday clinical trials of its experimental COVID-19 #vaccine resumed in Japan.https://t.co/enubUg9VQ6 pic.twitter.com/bSDa4lRQTp
— Arab News Japan (@ArabNewsjp) October 3, 2020
Major British drugmaker @AstraZeneca PLC said Friday that it has agreed with the Japanese government to launch negotiations on supplying #Japan with a #coronavirus vaccine currently under development with University of Oxford.https://t.co/OTrkWJzmHn pic.twitter.com/MYMrK1ZReE
— Arab News Japan (@ArabNewsjp) June 27, 2020
Japan's Prime Minister @AbeShinzo said Sunday that the country is in talks with pharmaceutical firms overseas to secure vaccines for the novel #coronavirus towards the end of the year.@AstraZenecahttps://t.co/k41GZj2afH pic.twitter.com/hKODrfAh5O
— Arab News Japan (@ArabNewsjp) June 14, 2020
.@AstraZeneca resumes #COVID19 #vaccine trial in Japan, U.S. still paused. https://t.co/reQEFIZw5M
— A Voice For Choice Advocacy (@avoiceforchoice) October 2, 2020
https://twitter.com/moneycontrolcom/status/1311949554284023808
Kudos to @AstraZeneca whose Breztri Aerospher has become the first triple-combination therapy for #COPD in a pressurized metered-dose #inhaler device to be approved in Japan. https://t.co/9KlWUm8B8t #NoblePharma #GoNoble
— Noble (@NoblePharma) August 9, 2019
Latest newsletter highlights: VivaGel BV European & AU launch, $SPL’s 2nd @AstraZeneca agreement, VivaGel condom launch in Japan w/ @Okamototown & our DEP programs https://t.co/mOVSIwGRZ6 #ASX pic.twitter.com/jK9jN33tY9
— Starpharma (@Starpharma_ASX) July 1, 2019
#AstraZeneca Reports Approval Of #Tagrisso In #Japan https://t.co/yEwHkUDRvG @RTTNews @AstraZeneca #osimertinib #NSCLC
— Plexus Ventures (@PlexusVentures) August 22, 2018
In industry news: Lynparza Approved in Japan for BRCA-Mutated Metastatic #BreastCancer @AstraZeneca @Merck https://t.co/rYdVMDnSfm pic.twitter.com/GEOQrnCUeQ
— Mammary Cell News (@MammaryCell) July 6, 2018
What possibilities for business with the #EU #Japan free trade agreement? Highly relevant seminar in Stockholm today by @BusinessSweden and @SweMFA, with opening by @AnnLinde. @AstraZeneca @BabyBjornSweden @Virtusize @Kommerskoll pic.twitter.com/D9A92vi2tC
— Anna Stellinger (@AnnaStellinger) March 28, 2018
Inflammatory Intestinal Diseases Findings: Efficacy & Safety of Oral #Budesonide in Patients with Active #Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study #Crohns @AstraZenecaSE @AstraZeneca @S_Karger_Japanhttps://t.co/bejGi7Mmg5 pic.twitter.com/hZnd8trekI
— Karger Open Access (@KargerOpen) November 28, 2017
Our employees from around the globe did their bit for #EarthDay at the weekend, with teams from Serbia, to Japan & the US joining the #EarthDayCleanUp19. Find out more about our approach to environmental protection as part of our sustainability strategy: https://t.co/1wtTM2Z3xp. pic.twitter.com/N2xBB4hMvh
— AstraZeneca (@AstraZeneca) April 25, 2019
Did you know that we have committed to moving 100% of our vehicle fleet across Europe, North America & Japan to hybrid, plug-in or electric by 2025? This is one of the ways we are working to #ActOnClimate earning us a spot on the @CDP #CDPAList: https://t.co/1g9MJYeXD3 pic.twitter.com/1KbqbupS7C
— AstraZeneca (@AstraZeneca) February 25, 2019
https://twitter.com/BCCJapan/status/1193767882334687232
https://twitter.com/BCCJapan/status/1071924366328258560
Phase III and Phase II/III clinical trials studying immunization for #RSV disease prevention for all infants have launched in Japan. We are pleased to partner with @AstraZeneca in an effort to reduce the burden of #RSV worldwide. Learn more here: https://t.co/a7KpuD4M4Z pic.twitter.com/7ven9yqeHK
— Sanofi (@sanofi) October 11, 2019
Astrazeneca Pharma initiates the commercial launch of XIGDUOA XR tablets in India. XIGDUOA XR is a product of @AstraZeneca Group approved in 61 countries including US, EU & Japan. It is used to treat type 2 diabetes mellitus pic.twitter.com/JqEBOjh5dJ
— CNBC-TV18 (@CNBCTV18Live) February 12, 2018
.@AstraZeneca enters agreement with Kyowa Hakko Kirin to commercialise antibody to treat asthma/COPD in Japan http://t.co/3yBVniGTW0 #pharma
— SartoriusRoyston (@TAPBiosystems) July 18, 2015
Grünenthal to Acquire AstraZeneca’s European rights to Nexium & Global (ex US & Japan) Rights to Vimovo for up to $922m https://t.co/uAVjxWY3IX @grunenthalgroup @AstraZeneca More European life science business news at [LSE] at https://t.co/8to5cxePG5 pic.twitter.com/lceOUo8wHH
— [iito] Life Science (@iitoLifeScience) October 30, 2018
AstraZeneca: Tagrisso Approved in Japan for 1st-line EGFR-mutated NSCLC https://t.co/FRUMYxZIYx @AstraZeneca More UK & Irish life science business news at [LSE] at https://t.co/ShKV2svWTv pic.twitter.com/XDjdQn2XTd
— [iito] Life Science (@iitoLifeScience) August 21, 2018
#AZN £63.74 After positive news: #Calquence trial✅#Lynparza approved in the #EU✅#Bevespi #Aerosphere approved by the #Japanese MH✅
Lynparza approved in #Japan✅
Breztri Aerosphere (PT010) approved in Japan✅https://t.co/pRRm18hjeI #COPD #PHARMA #AI pic.twitter.com/z0rSyl0eqz— Peter Higgins (conkers) (@conkers3) June 19, 2019
#AZN £59.90 #Tagrisso approved in #Japan for 1st-line treatment of EGFR-mutated non-small cell lung #cancer.
1st-line Tagrisso offers a potential new standard of care for Japanese lung cancer patients✅https://t.co/C8ZDZK9cuV #PHARMA #BIOTECH #BIOPHARMA #MEDTECH #AI #ML #SCIENCE pic.twitter.com/vCp7Y2yiWn— Peter Higgins (conkers) (@conkers3) August 21, 2018
#AZN +2% £53.59$AZN Regulatory submission in #Japan for #Forxiga in type-1 #diabetes✅ https://t.co/TLiZLg7L6I
US regulators finally approve @AstraZeneca' potential blockbuster #LOKELMA drug✅https://t.co/GDxPfuUR0D #PHARMA #BIOTECH #INVESTING #QARP pic.twitter.com/0P5FEP3J0E
— Peter Higgins (conkers) (@conkers3) May 21, 2018
#AZN+1% £50.36 @DigitalLookNews #AstraZeneca gets approvals for #Fasenra & #Lynparza in #Japan✅Lynparza is the first poly ADP-ribose polymerase (PARP) inhibitor to be approved in Japan✅ https://t.co/ErNbKkH0YE #bronchial #asthma #COPD $AZN #PHARMA #BIOTECH #BIOPHARMA #MEDTECH pic.twitter.com/QLyA8r41IC
— Peter Higgins (conkers) (@conkers3) January 19, 2018
.@AstraZeneca Q1 Results http://t.co/eYQpCrJ12W Growth platforms (Brilinta, diabetes, respiratory, Emerging Markets & Japan) +13% to $3.4Bn
— Peter Higgins (conkers) (@conkers3) April 24, 2015
#DRG epidemiology report estimates more than 35,000 newly diagnosed cases of #chroniclymphocyticleukemia across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #CLL #leukemia chronic #lymphocyticleukemia @AstraZeneca https://t.co/c93A2A45xs
— DRG Epidemiology (@DRG_Epi) December 2, 2019
#DRG epidemiology report estimates more than 3.5 million people affected with #hyperkalemia across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #kidney #KidneyWk #chronickidneydisease @AstraZeneca https://t.co/PV3qywDoqv
— DRG Epidemiology (@DRG_Epi) November 18, 2019
#DRG epidemiology report estimates over 35,000 newly diagnosed cases of #chroniclymphocyticleukemia across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #CLL #leukemia #lymphocyticleukemia #BloodCancerAwarenessMonth @AstraZeneca https://t.co/a86N2RqLkg
— DRG Epidemiology (@DRG_Epi) September 11, 2019
More than 7000 newly diagnosed #ovariancancer cases have #BRCA #mutations across the United States, Western Europe and Japan. Watch this space for more updates on #DRG global epidemiology data @DRGinsights #ovarian #cancer #biomarkers #tumors #genetictesting @AstraZeneca https://t.co/X2aYXDRkqQ
— DRG Epidemiology (@DRG_Epi) September 3, 2019
#DRG epidemiology report estimates more than 35,000 newly diagnosed cases of #chroniclymphocyticleukemia across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #CLL #leukemia chronic #lymphocyticleukemia @AstraZeneca https://t.co/dIbsLkOrVa
— DRG Epidemiology (@DRG_Epi) August 22, 2019
More than 3.5 million people are affected with #hyperkalemia across the United States, Western Europe and Japan. Follow us for more updates on #DRG epidemiology data on #hyperkalemia #CKD @DRGinsights @AstraZeneca #KidneyWk https://t.co/xOVhUSaqVL
— DRG Epidemiology (@DRG_Epi) October 25, 2018
#DRG reports more than 10 million cases living with #Alzheimers across the United States, Western Europe and Japan https://t.co/r92nrjx1mO @DRGinsights @AstraZeneca https://t.co/xk3LFosS3Q
— DRG Epidemiology (@DRG_Epi) August 3, 2018
Thanks to our @ANZUPtrials #bestofGUoncology #ANZUPGU19 sponsors – @IpsenGroup Astellas Oncology @AstraZeneca @MSD_Aus pic.twitter.com/WtTfQE1djd
— ANZUP (@ANZUPtrials) November 6, 2019
Thanks also to our #APCCC APAC Satellite Symposium sponsors Astellas @AstraZeneca @IpsenGroup @JanssenANZ and Tolmar #APCCCinAPAC18 pic.twitter.com/AnrhNOAxuu
— ANZUP (@ANZUPtrials) February 23, 2018
.@MeetingsShow’s healthcare education speakers to include @AstraZeneca and Astellas: http://t.co/EtOBMyb9Q5 #TMS15 pic.twitter.com/xlnTvYk3fr
— Soaring Worldwide (@SoaringWW) June 16, 2015
United States Shingles Vaccine Market @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech #shingles #zoster #vaccine https://t.co/DIBnqocTp0 via @dpiresearch
— DPI Research (@DPIResearch) October 14, 2020
Vaccines Market Booming Worldwide With Leading Players https://t.co/yVs3yTmMC8 @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech
— DPI Research (@DPIResearch) September 28, 2020
United States Influenza Vaccines Market Forecast 2020 – 2027 https://t.co/ovFvfMYYfI @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech
— DPI Research Official (@dpi_research) August 28, 2020
I just published US Influenza(Flu) Vaccine Market https://t.co/I0te2HEkCW @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech
— DPI Research Official (@dpi_research) August 27, 2020
Analyst Keshalini Sabaratnam @Pharma_GD on the #sales #forecast for @Merck and #Otsuka 's #Keytruda (pembrolizumab) projected to be top drug by 2023 and what does this mean for their #contractmanufacturers #CDMO #CMO @AstraZeneca @BoehringerDE https://t.co/R6Wmwcm2Qb
— GlobalData PharmSource (@PharmSource) October 2, 2019
#Innovation #Index #Pharma @baxter_intl @Celgene #Otsuka @AstraZeneca @Roche @Novartis… https://t.co/zzzaGWoCii pic.twitter.com/sbAEuYm54a
— Biotechin.asia (@biotechinasia) April 10, 2016
AstraZeneca and Eisai make EMA demands:
The European Medicines Agency will relocate from the UK in light of Brexit. https://t.co/plD7JJnH1z @AstraZeneca #Eisai #EMA @EMA_News #Brexit #medicine #health #Lifesciences— LifeSciencesIPReview (@LifeSciencesIPR) January 10, 2018
.@AstraZeneca and Eisai support continued @EMA_News oversight of drugs and safety on both sides of the Channel. Minimum demand is “mutual recognition” of medicines standards. #Brexit https://t.co/2RNHEIPPMA
— RegMedNet (@RegMedNet) January 9, 2018
On #WorldNTDDay we celebrate our industry partnerships to #beatNTDs including the innovative Drug Discovery Booster to discover new drugs with @abbvie @AstellasUS @AstraZeneca @bmsnews @Eisai_SDGs @merckgroup Shionogi & @TakedaPharma. pic.twitter.com/j4Xgs60vO2
— Drugs for Neglected Diseases initiative (@DNDi) January 30, 2020
DNDi partners with Eisai, Shionogi, Takeda, and @AstraZeneca to find new treatments for #Chagas and #leishmaniasis http://t.co/ZA64pVAEhE
— Drugs for Neglected Diseases initiative (@DNDi) May 29, 2015
Huge thanks to @wellcometrust for having confidence in us. Terrific to be working in partnership with @turinginst to combine scientific excellence with commitment to improve the working environment for trainees with @NHSDigital @eisai @gsk @AstraZeneca @Microsoft @intel @iqvia https://t.co/bjIYmMhDH0
— Andrew Morris (@profadmorris) September 16, 2019
Excellent dialogue b/t #GlobalHealth leaders, philanthropic pharm. cos. @AstraZeneca @Eisai and NGOs @DND about partnerships to #CombatNTDs pic.twitter.com/jQwl8S8XAP
— MAP International (@mapintl) October 27, 2017
The 2020 Pharmaceutical Innovation and Invention Index is live at @FortuneMagazine: https://t.co/dLQhy8vDMF
2020 Innovation Index
1 @Roche
2 @abbvie
3 @Novartis
3 @VertexPharma
5 @LillyPad
6 @AstraZeneca
7 @AlexionPharma
8 @Merck
9 Shionogi
10 @JNJNews
10 @Regeneron— Mike Rea, IDEA Pharma (@ideapharma) April 6, 2020
.@purduepharma and Shionogi take on @AstraZeneca, @Valeant in opioid-induced constipation. https://t.co/KaqgT4sAnO #DrugApproval $AZN $VRX pic.twitter.com/LlFIXx79wf
— FiercePharma (@FiercePharma) March 24, 2017
Vaccines Market Booming Worldwide With Leading Players @SanofiPasteur @GSK @Merck @Pfizer @AstraZeneca @Mitsubishi @emergentbiosolu @AstellasPharma @Valneva @Seqirus @CSLLimited @BavarianNordic @Sinovac @PanaceaBiotec @Dynavax @Grifols https://t.co/G6av4krbos via @dpiresearch
— DPI Research (@DPIResearch) October 5, 2020
Check out my latest article: Flu Vaccines Market Worth $7.5bn by 2027
https://t.co/ZbzwVCpnrq via @LinkedIn @SanofiPasteur @GSK @Merck @Pfizer @AstraZeneca @Mitsubishi @EmergentBioSolutions@AstellasPharma @Valneva @Seqirus @CSLLimited @BavarianNordic @Sinovac @PanaceaBiotec— DPI Research (@DPIResearch) October 7, 2020
https://t.co/6rgVwPyvqg @SanofiPasteur @GSK @Merck @Pfizer @AstraZeneca @Mitsubishi @EmergentBioSolutions@AstellasPharma @Valneva @Seqirus @CSLLimited @BavarianNordic @Sinovac @PanaceaBiotec @Dynavax @Grifols
— DPI Research (@DPIResearch) October 11, 2020
#ImaginAb joins with #AstraZeneca, #Pfizer and #Takeda to develop #tumourimaging #tech https://t.co/ccUgDG0BiV via @pharmaphorum @AstraZeneca @pfizer @TakedaPharma #technology #immunotherapies
— Plexus Ventures (@PlexusVentures) October 14, 2019
“@Novavax has signed similar deals with the UK, India, the Czech Republic, South Africa & Japan to supply doses of the potential #vaccine… [The Canadian government] is also in the final stages of negotiations with drug firm @AstraZeneca…” #COVID19 https://t.co/1qusqAiqJQ
— Mark Warner (@MAAWLAW) August 31, 2020
Takeda teams up with Novavax to introduce its coronavirus vaccine in Japan | @Takedapharma @Novavax @Pfizer @BioNTech @AstraZeneca @UniofOxford #Vaccines #Covid19 #Biotech #MatrixM #Maryland #OperationWarpSpeed @JNJ https://t.co/82tpoKazFb
— Aspen Biosciences (@aspenbio) August 9, 2020
Experts at @Astrazeneca, @Takeda and @Novartis tell us how to strengthen the collaboration and improve trust with patient community https://t.co/2sffvRXmJE #patients #patientcentricity #efppatients pic.twitter.com/QCW22ABoH2
— The Pharmaceutical Marketing Group (@PharmaMKTnet) September 28, 2019
Wrote about @AstraZeneca's new $1 billion plan to go carbon-zero by 2025 (carbon-neutral by 2030), and just how bad US-based big Pharma is
(Other Pharmas with near-term carbon-neutral plans: Novo Nordisk, Takeda and Novartis, all 3 EU or Japan-based)https://t.co/eqmNeLflQv
— Jason Mast (@Jasonmmast) January 23, 2020